Recro Pharma Inc (REPH) 8.02 $REPH Recro Pharma to

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Recro Pharma Inc (REPH) 8.02 $REPH

Recro Pharma to Present at the Jefferies 2016 Global Healthcare Conference
GlobeNewswire - Thu Jun 02, 6:00AM CDT
Recro Pharma, Inc. (Nasdaq:REPH), a revenue generating specialty pharmaceutical company focused on products for hospital and ambulatory care settings that is currently developing non-opioid products for the treatment of serious acute pain, today announced that Gerri Henwood, the Company's President and Chief Executive Officer, will present at the Jefferies 2016 Global Healthcare Conference on Thursday, June 9, 2016 at 11:00 am EDT. The conference is being held at the Grand Hyatt in New York City.
REPH: 8.02 (+0.07)

Recro Pharma reports 1Q loss
Automated Insights - Thu May 12, 8:16AM CDT
MALVERN, Pa. (AP) _ Recro Pharma Inc. (REPH) on Thursday reported a loss of $6.5 million in its first quarter.
REPH: 8.02 (+0.07)

Recro Pharma Presents Clinical Data at American Pain Society 35th Annual Scientific Meeting
GlobeNewswire - Thu May 12, 8:00AM CDT
Recro Pharma, Inc. (Nasdaq:REPH), a revenue generating specialty pharmaceutical company developing non-opioid products for the treatment of serious acute pain, today announced a poster presentation at the American Pain Society's 35 Annual Scientific Meeting, taking place May 11-14, 2016, in Austin, TX. The poster presentation highlights data from a clinical trial evaluating the efficacy and safety of intravenous (IV) meloxicam (N1539), in subjects with moderate to severe pain following open abdominal hysterectomy.
REPH: 8.02 (+0.07)

Recro Pharma (REPH) Looks Good: Stock Adds 5% in Session
Zacks Equity Research - Zacks Investment Research - Thu Apr 07, 7:40AM CDT
Recro Pharma, Inc. (REPH) saw its shares rise 5% in the last trading session.
ADHD: 4.68 (-0.18), REPH: 8.02 (+0.07)

Recro Pharma Reports Year End 2015 Financial Results
GlobeNewswire - Thu Mar 24, 7:20AM CDT
Recro Pharma, Inc. (Nasdaq:REPH), a revenue generating specialty pharmaceutical company developing multiple non-opioid therapeutics for the treatment of serious acute pain, today reported financial results for the year ended December 31, 2015.
REPH: 8.02 (+0.07)

Recro Pharma to Present at the 28th Annual ROTH Conference
GlobeNewswire - Mon Mar 07, 7:00AM CST
Recro Pharma, Inc. (Nasdaq:REPH), a revenue generating specialty pharmaceutical company developing multiple non-opioid therapeutics for the treatment of pain, today announced that Gerri Henwood, the Company's President and Chief Executive Officer, will present at the 28 Annual ROTH Conference on Monday, March 14, 2016 at 5:30 pm PST. The conference is being held at the Ritz Carlton Hotel in Dana Point, CA.
REPH: 8.02 (+0.07)

Recro Pharma to Present at NobleCon12 Investor Conference
GlobeNewswire - Thu Jan 14, 12:19PM CST
Recro Pharma, Inc. (Nasdaq:REPH), a revenue generating specialty pharmaceutical company developing multiple non-opioid therapeutics for the treatment of pain, today announced that Gerri Henwood, the Company's President and Chief Executive Officer, will present at Noble Financial Capital Markets' 12th Annual Investor Conference (NobleCon12) on Tuesday, January 19, 2016 at 4:00 pm EST. The conference is being held at Club Med in Sandpiper Bay, Florida.
REPH: 8.02 (+0.07)

Global Acute Pain Therapeutics Pipeline Review, H2 2015
M2 - Thu Jan 07, 10:44AM CST
Research and Markets (http://www.researchandmarkets.com/research/k9flzp/acute_pain) has announced the addition of the "Acute Pain - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Acute Pain, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Acute Pain and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Acute Pain Overview - Therapeutics Development - Pipeline Products for Acute Pain - Overview - Pipeline Products for Acute Pain - Comparative Analysis - Acute Pain - Therapeutics under Development by Companies - Acute Pain - Therapeutics under Investigation by Universities/Institutes - Acute Pain - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Acute Pain - Products under Development by Companies - Acute Pain - Products under Investigation by Universities/Institutes - Acute Pain - Companies Involved in Therapeutics Development - A. Menarini Industrie Farmaceutiche Riunite Srl - AcelRx Pharmaceuticals, Inc. - Adynxx, Inc. - Amorsa Therapeutics Inc. - AnaBios Corporation - Anavex Life Sciences Corp. - AngioChem Inc. - Antibe Therapeutics, Inc. - AskAt Inc. - Cara Therapeutics, Inc. - Centrexion Corporation - Charleston Laboratories, Inc. - ChironWells GmbH - Cytogel Pharma, LLC - Dompe Farmaceutici S.p.A. - Grunenthal GmbH - INSYS Therapeutics, Inc. - Iroko Pharmaceuticals, LLC - KemPharm, Inc. - Kineta, Inc. - Laboratorios Del Dr. Esteve S.A. - Mallinckrodt Plc - MEDRx Co., Ltd. - Nanomerics Ltd - Nektar Therapeutics - Nuvo Research Inc. - Orbis Biosciences, Inc. - Orexo AB - Orion Oyj - Pacira Pharmaceuticals, Inc. - Phosphagenics Limited - Recro Pharma, Inc. - Shulov Innovative Science Ltd. - Sigma-Tau S.p.A. - Syntrix Biosystems, Inc. For more information visit http://www.researchandmarkets.com/research/k9flzp/acute_pain
ACRX: 2.95 (-0.03), KMPH: 4.11 (-0.18), NKTR: 15.06 (+0.14), INSY: 15.61 (-0.05), AVXL: 7.80 (+0.22), PCRX: 36.30 (-0.09), REPH: 8.02 (+0.07), PTIE: 2.25 (+0.01)

The Zacks Analyst Blog Highlights: Eagle Pharmaceuticals, Recro Pharma, Amazon.com, Energy Focus and NVIDIA
Zacks Equity Research - Zacks Investment Research - Wed Jan 06, 8:30AM CST
The Zacks Analyst Blog Highlights: Eagle Pharmaceuticals, Recro Pharma, Amazon.com, Energy Focus and NVIDIA
AMZN: 753.72 (+7.91), EFOI: 5.73 (unch), EGRX: 43.59 (+0.81), REPH: 8.02 (+0.07), NVDA: 52.10 (+1.25)

Recro Pharma Reports Positive Top-Line Results for Phase II Clinical Trial of IV Meloxicam
GlobeNewswire - Wed Jan 06, 6:00AM CST
IV Meloxicam Well Tolerated with Statistically Significant Analgesic Effect Reported
REPH: 8.02 (+0.07)

Buffett Fans Take Note: 5 Stocks That Crushed Berkshire Hathaway in 2015
Zacks Equity Research - Zacks Investment Research - Tue Jan 05, 12:23PM CST
There is no doubt that Berkshire Hathaway Inc. (BRK.B) is a stock that most investors want in their portfolio.
AMZN: 753.72 (+7.91), EFOI: 5.73 (unch), AXP: 62.10 (+0.61), IBM: 155.32 (+0.86), EGRX: 43.59 (+0.81), BRK.B: 143.87 (+0.22), REPH: 8.02 (+0.07), NVDA: 52.10 (+1.25)

5 Small Cap ETFs & Stocks that Beat Russell 2000 in 2015
Sweta Killa - Zacks Investment Research - Mon Jan 04, 9:59AM CST
These ETFs and stocks have shown strong resilience to the sharp downturn in the small cap space and the trend is likely to continue, making these lucrative picks for 2016.
PSCH: 73.55 (+0.36), NPTN: 9.94 (+0.05), LPTH: 1.65 (unch), REPH: 8.02 (+0.07), PSCT: 56.70 (+0.36), PSCU: 49.30 (-0.22)

The Zacks Analyst Blog Highlights: Eagle Pharmaceuticals, Recro Pharma, Energy Focus, Hanwha Q CELLS and LightPath Technologies
Zacks Equity Research - Zacks Investment Research - Tue Dec 29, 8:30AM CST
The Zacks Analyst Blog Highlights: Eagle Pharmaceuticals, Recro Pharma, Energy Focus, Hanwha Q CELLS and LightPath Technologies
EFOI: 5.73 (unch), LPTH: 1.65 (unch), EGRX: 43.59 (+0.81), REPH: 8.02 (+0.07), HQCL: 14.63 (+0.21)

Recro Pharma Appoints Stewart McCallum, MD, as Chief Medical Officer
GlobeNewswire - Wed Dec 02, 6:00AM CST
Recro Pharma, Inc. (Nasdaq:REPH), a revenue generating specialty pharmaceutical company developing multiple non-opioid therapeutics for the treatment of pain, today announced the appointment of Stewart McCallum, M.D., as Chief Medical Officer.
REPH: 8.02 (+0.07)

Recro Pharma to Present at the 2015 Piper Jaffray Healthcare Conference
GlobeNewswire - Tue Nov 24, 6:00AM CST
Recro Pharma, Inc. (Nasdaq:REPH), a revenue generating specialty pharmaceutical company developing multiple non-opioid therapeutics for the treatment of pain, today announced that Gerri Henwood, the Company's President and Chief Executive Officer, will present at the 2015 Piper Jaffray Healthcare Conference on Tuesday, December 1, 2015 at 9:10 am EST. The conference is being held at the Lotte New York Palace Hotel in New York City.
REPH: 8.02 (+0.07)

Recro Pharma Reports Third Quarter 2015 Financial Results
GlobeNewswire - Fri Nov 13, 5:59AM CST
Recro Pharma, Inc. (Nasdaq:REPH), a revenue generating specialty pharmaceutical company developing multiple non-opioid therapeutics for the treatment of pain, today reported financial results for the third quarter ended September 30, 2015.
REPH: 8.02 (+0.07)

Recro Pharma to Participate in Upcoming Investor Conferences
GlobeNewswire - Thu Nov 12, 6:00AM CST
Recro Pharma, Inc. (Nasdaq:REPH), a revenue generating specialty pharmaceutical company developing multiple non-opioid therapeutics for the treatment of pain, today announced that Gerri Henwood, the Company's President and Chief Executive Officer, will participate in the following upcoming investor conferences:
REPH: 8.02 (+0.07)

Recro Pharma Provides Pipeline Update
GlobeNewswire - Mon Oct 26, 7:00AM CDT
IV Meloxicam Advancing to Phase III; Pivotal Trials Expected to Commence in First Quarter 2016
REPH: 8.02 (+0.07)

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Alibaba Lawsuit Deadline Puts Disclosure Risk in Focus

Updated Category News Views 209

A calendar deadline is doing more work than any earnings headline for Alibaba shareholders this week. A securities class action notice says investors who bought or acquired Alibaba Group Holding Limited securities between May 23, 2024 and November 11, 2026 may seek appointment as lead plaintiff by January 19, 2027. That is a procedural milestone, not a verdict, and...

Continue Reading
Charter Investigation Puts ACP Exit Claims Under Lens

Updated Category News Views 258

Charter’s ACP hangover has grown from an operating headache into a governance question. Kahn Swick & Foti said on November 20, 2026, that it has begun investigating whether Charter Communications officers or directors breached fiduciary duties or otherwise broke state or federal law. That is not a finding of wrongdoing, and investors ought to keep that distinction...

Continue Reading
Domino's Probe Puts Franchise Disclosure Under Lens

Updated Category News Views 195

A franchisee's shuttered stores can turn cheerful unit-growth talk into a nasty accounting of credibility, and that is the uncomfortable territory Domino's now occupies. Kahn Swick & Foti has opened an investigation into whether Domino's officers and directors breached fiduciary duties or violated state or federal law. That is not a finding of misconduct. It is a legal...

Continue Reading
UAE Trust Model Faces Its Hardest Test During Crisis

Updated Category News Views 176

A country’s reputation is usually invisible right up until the machinery rattles. Then people, investors, trading partners and residents stop listening to polished slogans and start watching whether airports function, services hold up, information arrives, and business can keep moving. That was the useful core of Saeed Al Eter’s remarks at Ajman Media Forum 2026: soft...

Continue Reading
Persistent Dry Eye Symptoms Call for a Closer Look

Updated Category News Views 150

Eyes can turn into a stubborn little nuisance long before people realize something more complicated is going on. A bottle of artificial tears is easy to grab, cheap enough, and often perfectly sensible for a rough day of screens, wind, reading, or air conditioning. But Dr. Harlan Snyder’s point is the one worth sitting with: when dryness keeps barging back despite...

Continue Reading
CCAPP Holiday Training Targets Seasonal Recovery Strain

Updated Category News Views 126

December cheer has a nasty habit of hiding the people barely holding themselves together. CCAPP’s upcoming virtual workshop, Hope for the Holidays: Understanding Depression, Stress & Resilience During the Holiday Season, takes that uncomfortable reality seriously rather than treating it like a seasonal footnote. For behavioral health workers supporting people in...

Continue Reading
PHONO's 150 MW RE+ Win Tests Its U.S. Solar Staying Power

Updated Category News Views 118

A trade-show order book is not cash in the bank, but 150 MW is still a number worth circling in red. PHONO used RE+ 2026 in Las Vegas, held November 17 through 19, to celebrate 20 years in business, parade its solar and storage lineup, and announce new U.S. orders. In a solar market that has become touchier about provenance, compliance and delivered economics, the company...

Continue Reading
ModuleMD Takes Allergy EHR AI Beyond the Usual Hype Cycle

Updated Category News Views 215

Allergy Workflows Are Where This Has to Earn Its Keep Allergy clinics do not need another shiny dashboard clogging up a workstation. They need less typing, fewer handoffs, cleaner documentation, and fewer administrative chores slipping through the cracks while a packed day keeps moving. That is the practical lens for ModuleMD's ACAAI 2026 presentation in Phoenix: not...

Continue Reading
Mission Inn’s Lights Enter a Tender New Ownership Era

Updated Category News Views 112

A holiday spectacle can outlive the hands that hung its first bulb. Riverside is about to test that truth in public, under millions of tiny lights and the very large shadow of a family departure. The Mission Inn Festival of Lights returns in 2026 without Kelly and Duane Roberts as hotel owners for the first time in more than three decades. Duane Roberts died in 2025, the...

Continue Reading
Human Frontier Mission Puts AI Research on Display

Updated Category News Views 154

A laboratory notebook is about to become the real product in this AI experiment. Human Frontier Mission, or HFM, says it will launch globally on Nov. 24, opening a research program where domain specialists frame scientific and engineering problems while autonomous AI agents develop and test possible answers. The unusual bit is not merely handing models difficult work. It...

Continue Reading

Top 5 Most Recently Viewed Articles

Exploring the Future of Hydrogen Detection Technology and Growth

Updated Category News Views 545

Hydrogen Detection Market Size & Growth Insights The hydrogen detection market is on a remarkable trajectory, aiming to reach an impressive USD 642.39 million by 2032. This growth represents a substantial compound annual growth rate (CAGR) of 11.89% from 2024 to 2032, starting with a market valuation of USD 234.9 million in 2023. The ongoing emphasis on hydrogen as a...

Continue Reading
Insights into Novonesis’ Share Buyback Program Transactions

Updated Category News Views 336

Understanding Novonesis’ Share Buyback Program The financial landscape continuously evolves, and one significant strategy that companies often utilize is a share buyback program. Novonesis is currently engaging in such a strategy, which has piqued the interest of many investors and market analysts alike. This program allows a company to repurchase its shares from the...

Continue Reading
Discover Chippewa Boots' Newest October Selection for Workers

Updated Category News Views 250

October Boot of the Month: The Paladin and Tinsley Chippewa Boots proudly presents its October Boot of the Month: the Paladin and Tinsley, both exceptional 8-inch Waterproof Insulated Steel Toe Loggers. These boots are designed to excel in tough work environments while providing the necessary protection, comfort, and performance that professionals need. Features of the...

Continue Reading
Understanding Broadcom's Recent Options Activity and Insights

Updated Category News Views 100

Broadcom's Options Activity: What Investors Are Observing Investors with considerable capital are showing a notable interest in Broadcom (NASDAQ: AVGO), currently adopting a more cautious stance than usual. This trend is captured through significant options activity that market players should closely monitor. While the identities of these investors remain undisclosed, the...

Continue Reading
Santa Clara University Celebrates Diverse Class of 2028

Updated Category News Views 597

Welcoming a New Era at Santa Clara University Santa Clara University has kicked off a new chapter with over 1,800 enthusiastic undergraduates joining the ranks during a lively Welcome Weekend. This event was not just about filling seats; it was a whirlwind of social gatherings—from dance parties to heartfelt ceremonies—showing SCU’s determination to cultivate an...

Continue Reading